On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41$71.63 per share on August 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class ...